- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
May 14th, 2007
Midatech, the UK group exploring the therapeutic and diagnostic applications of nanoparticles as drug delivery vehicles, scaffolds for synthetic vaccines or antibiotics and non-invasive imaging agents, aims to put its first product into clinical trials in the first quarter of 2008.
This will be multivalent antibiotics delivered on nanoparticles, said Midatech's Storme Thornicroft. The group's listed pipeline includes a project coded MTL 201 that involves antibiotics for the treatment of the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA).
|Related News Press|
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016